ELXR:CA:TSV-Elixxer Ltd (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1.15

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

5.50K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

N/A

USD 0.10B
LOVE:CA Cannara Biotech Inc

-0.03 (-3.61%)

USD 0.08B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.07B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.05B
LSL:CA LSL Pharma Group Inc.

N/A

USD 0.04B
PCLO:CA Pharmacielo Ltd

-0.01 (-5.41%)

USD 0.03B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

+0.01 (+1.37%)

USD 0.02B
NDVA:CA Indiva Ltd

N/A

USD 0.01B
DHB:CA Delivra Health Brands Inc.

N/A

USD 0.01B

ETFs Containing ELXR:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 23.41% 90% A- 72% C
Dividend Return 23.41% 90% A- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 558.03% 5% F 2% F
Risk Adjusted Return 4.20% 62% D 54% F
Market Capitalization 0.01B 59% D- 60% D-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector